Oral Antibiotic Treatment of Mice Exacerbates the Disease Severity of Multiple Flavivirus Infections

Larissa B. Thackray(Washington University in St. Louis), Scott A. Handley(Washington University in St. Louis), Matthew J. Gorman(Washington University in St. Louis), Subhajit Poddar(Washington University in St. Louis), Prachi Bagadia(Washington University in St. Louis), Carlos G. Briseño(Washington University in St. Louis), Derek J. Theisen(Washington University in St. Louis), Qing Tan(Washington University in St. Louis), Barry L. Hykes(Washington University in St. Louis), Hueylie Lin(Washington University in St. Louis), Tiffany M. Lucas(Washington University in St. Louis), Chandni Desai(Washington University in St. Louis), Jeffrey I. Gordon(Washington University in St. Louis), Kenneth M. Murphy(Howard Hughes Medical Institute), Herbert W. Virgin(Washington University in St. Louis), Michael Diamond(Washington University in St. Louis)
Cell Reports
March 1, 2018
Cited by 139Open Access
Full Text

Abstract

T cells associated with increased infection and immunopathology. Abx treatments that resulted in enhanced WNV susceptibility generated changes in the overall structure of the gut bacterial community and in the abundance of specific bacterial taxa. As little as 3 days of treatment with ampicillin was sufficient to alter host immunity and WNV outcome. Our results identify oral Abx therapy as a potential environmental determinant of systemic viral disease, and they raise the possibility that perturbation of the gut microbiota may have deleterious consequences for subsequent flavivirus infections.


Related Papers

No related papers found

Powered by citation graph analysis